134 research outputs found
Effect of Urea Inclusion in Diets Containing Distillers Grains on Feedlot Cattle Performance and Carcass Characteristics
No full textCeconi, I.; DiCostanzo, A.; Crawford, G. I.. (2012). Effect of Urea Inclusion in Diets Containing Distillers Grains on Feedlot Cattle Performance and Carcass Characteristics. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/204297
Rumen Degradable Protein in Feedlot Diets
No full textCeconi, Irene; Crawford, Grant I.; DiCostanzo, Alfredo. (2013). Rumen Degradable Protein in Feedlot Diets. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/204374
Selective and specific<i>I</i><sub>f</sub>inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease
No full textHeart rate is a major determinant of myocardial oxygen demand and supply, and increased heart rate adversely affects the pathophysiology of myocardial ischemia. High resting heart rate is a risk factor in cardiovascular disease. The development of the heart rate-lowering agent ivabradine showed that heart rate was also an important treatment target, notably in coronary artery disease and heart failure. Indeed, heart rate reduction with ivabradine, a selective and specific I f inhibitor, reduces myocardial oxygen demand, increases diastolic perfusion time and improves energetics in ischemic myocardium. Ivabradine protects the myocardium during ischemia, improves left ventricular function in heart failure and reduces remodeling following myocardial infarction. It improves prognosis in patients with coronary artery disease, left ventricular dysfunction and heart rate ≥70 beats per minute, as well as in patients with heart failure and left ventricular dysfunction. Ivabradine is safe, well tolerated and can be used in combination with the main drugs for cardiovascular disease. © 2011 Expert Reviews Ltd
INIBIZIONE SELETTIVA E SPECIFICA DEI CANALI IF CON UNA NUOVA MOLECOLA PER LA TERAPIA DELLE MALATTIE CARDIOVASCOLARI / SELECTIVE AND SPECIFIC IF INHIBITION WITH NEW MOLECULE: NEW PERSPECTIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASE
No full textLdaia Fcroe qedu eunnz aa uCmaredniatoc ad (eFllCa )f rèe quune enlzeam ceanrtdoia dceat perumò indaivnetnet adreel lcao cnasuusma osc dait eonsasingteen fios idoepl amtouloscgoicloa dcaerl-- ln’ieslclah emmailaa tmtiaio ccaarrddiiocvaa. sLc’oaluamree. nLtaa stcao fpreeqrtuae en zl’aa pcparlidciaazciao nae rciplinoiscoa èd ic uonnas idneuroavtaa muno lfeactotolar ec hdei aribscbhaiso- rsoa nlaa rFicCa h(aC AdiDm) oes tnraetlloo cshceo mqupeesntsao è caanrdchiaec ou n( SimC)p. oErftfaentttiev aombeienttteiv,o i ln deel ctrreamttaemnteon tdoe ldlae lflrae mquaelantztaia c caor-- ldai arcicah oietsttean udti oo scsoigne qnuoe dsteol mnuioocvaor dfaiorm, aaucmo,e unnta i nlaib piteorrfue ssioelneett idvioa seto slpiceac eifi cmoi gdleiollraa cl’oarprepnotreto I fe, nriedrugcee- ztiicoon ea l vmeniotrciacrodlaiore i sscihneismtraic on.e Lll’oIv aSbCr,a ed inriad upcreo tiel grgime oild melliaomcaerndtioo dmuiroacnatred ilc’iosc choenmsieag, umenigtleio arall ’ilna ffaurtno- caacrudtoia.c Ma ?ig7l0io brap mla , psriao gnneoi psia sziiae nntei ic ponaz SieCn tei dcoisnfu CnzAioDn, ed diseful nvezinotnriec ovleon stirnicisotlraor.e L s’Iivnaisbtrraad, ien afr èe quune nfazra- mmaalcaot tsiaic cuarord, iobveans ctoolllaerrea.t
Efficacy of Ivabradine in Combination with Beta-Blocker Versus Uptitration of Beta-Blocker in Patients with Stable Angina
No full textPurpose The antianginal and anti-ischemic efficacy of the
selective If inhibitor ivabradine is established in patients with
stable angina in monotherapy and in combination with other
antianginals, including beta-blocker. This pilot study compared
the antianginal and anti-ischemic efficacy and hemodynamic
profile of ivabradine plus 5 mg bisoprolol versus
those of 10 mg bisoprolol in patients with stable angina.
Patients and methods Twenty-nine patients with stable
angina and moderate left ventricular systolic dysfunction
already on bisoprolol 5 mg od were randomized into 2
groups. Group 1 (n=17) received ivabradine (5–7.5 mg bid)
in addition to bisoprolol 5 mg od, while in group 2 (n=12)
bisoprolol was uptitrated first to 7.5 mg and then 10 mg od.
Patients underwent a treadmill test, 6-minute walking test,
and echocardiography at baseline and after 2 months.
Results Mean resting heart rate decreased in both groups,
from 76.6±4.6 bpm to 59.3±2.5 bpm (P<0.001) in group 1
and from 75.9±3.0 bpm to 60.5±2.3 bpm (P=0.002) in
group 2. The effect on resting heart rate did not differ
significantly between the two groups. However, more
patients became asymptomatic in group 1 than in group 2.
Addition of ivabradine also improved exercise capacity, as
shown by the results of the 6-minute walking and exercise
tolerance tests, whereas in group 2 neither parameter was
significantly affected. Chronotropic reserve significantly
improved with ivabradine, but not with bisoprolol 10 mg.
Conclusions These results suggest that combining ivabradine
with low dose bisoprolol in stable angina patients produces
additional antianginal and anti-ischemic benefits and improves
chronotropic reserve
Anti-ischaemic effect of ivabradine
No full textIvabradine, the first representative of a new class of exclusive heart rate-reducing agents, selectively inhibits the I(f) current in the sinoatrial node. The direct electrophysiological consequence of this inhibition is a reduction in the slope of the diastolic depolarisation curve and a decrease in heart rate. Pharmacological inhibition of the I(f) current with ivabradine has been shown to preserve coronary vasodilatation upon exercise, i.e., myocardial perfusion, with no negative inotropic effects and maintenance of cardiac contractility. Ivabradine protects the myocardium during ischaemia, improves left ventricular function in congestive heart failure, and reduces remodelling subsequent to myocardial infarction. Pure heart rate reduction by specific and selective I(f) inhibition decreases oxygen demand, improves myocardial energetics and improves perfusion of the ischaemic myocardium. We can expect distinct clinical benefits from long-term heart rate reduction in patients with chronic ischaemic diseas
The heart rate story
No full textThe role of heart rate is well established in the development and pathophysiology of myocardial ischaemia. In patients with coronary artery disease, most ischaemic episodes are triggered by an increase in heart rate, which induces an imbalance between myocardial oxygen delivery and consumption. Therefore, heart rate reduction has been considered as an important therapeutic approach in preventing ischaemia by reducing myocardial oxygen consumption and improving myocardial perfusion, by prolonging the diastolic interval. In addition to the beneficial effects of heart rate reduction for the prevention of ischaemia, a lower heart rate is associated with a more favourable prognosis. Recently, prospective investigation of the prognostic role of resting heart rate in patients with coronary artery disease and left ventricular systolic dysfunction, using the placebo arm of the BEAUTIFUL study, showed that elevated heart rate was associated with an increased risk of adverse fatal and non-fatal cardiac events. Ivabradine is a new medication which lowers heart rate by selectively inhibiting the If current, without other direct cardiovascular effects. Therefore, ivabradine opens up new opportunities in the management of patients with coronary artery disease. © The Author 2011
L'attivita' del conte Ceconi inquadrata quale promotore del turismo moderno attraverso lo sviluppo del sistema dei trasporti ferroviari internazionali
No full text- …
